Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - sugammadex sodium, quantity: 217.6 mg (equivalent: sugammadex, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sugammadex sodium, quantity: 554 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - sugammadex arx is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - sugammadex sodium (unii: erj6x2mxv7) (sugammadex - unii:361lpm2t56) - sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.  pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co. inc.’s bridion ® (sugammadex injection). however, due to merck sharp & dohme corp., a subsidiary of merck & co. inc.’s marketing exclusivity rights, this drug product is not labeled with that information. sugammadex is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex [see warnings and precautions (5.1), adverse reactions (6)].  risk summary  there are no clinical trial data on sugammadex use in pregnant women to inform any drug-associated risks. the available data from

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.